Your browser doesn't support javascript.
loading
Why we need more collaboration in Europe to enhance post-marketing surveillance of vaccines.
Sturkenboom, Miriam; Bahri, Priya; Chiucchiuini, Antonella; Grove Krause, Tyra; Hahné, Susan; Khromava, Alena; Kokki, Maarit; Kramarz, Piotr; Kurz, Xavier; Larson, Heidi J; de Lusignan, Simon; Mahy, Patrick; Torcel-Pagnon, Laurence; Titievsky, Lina; Bauchau, Vincent.
  • Sturkenboom M; Julius Global Health, University Medical Center Utrecht, Heidelberglaan 100, the Netherlands; VACCINE.GRID, Spitalstrasse 33, Basel, Switzerland; P-95, Koning Leopold III laan 1, 3001 Heverlee, Belgium. Electronic address: m.c.j.sturkenboom@umcutrecht.nl.
  • Bahri P; European Medicines Agency, 30 Churchill Pl, Canary Wharf, London E14 5EU, UK. Electronic address: Priya.Bahri@ema.europa.eu.
  • Chiucchiuini A; Takeda Pharmaceuticals International GmbH, Thurgauerstrasse 130, 8152 Glattpark, Switzerland. Electronic address: Antonella.Chiucchiuini@takeda.com.
  • Grove Krause T; Department of Infectious Disease, Epidemiology and Prevention, Statens Serum Institut, Artillerivej 3, DK-2100, Denmark. Electronic address: TGV@ssi.dk.
  • Hahné S; National Institute for Public Health and the Environment, PO Box 1, 3720 BA Bilthoven, the Netherlands. Electronic address: susan.hahne@rivm.nl.
  • Khromava A; Sanofi Pasteur, 1755 Steeles Ave W, North York, ON M2R 3T4, Canada. Electronic address: Alena.Khromava@sanofi.com.
  • Kokki M; European Center for Disease Prevention and Control, Gustav III:s boulevard 40, 169 73 Solna, Sweden. Electronic address: Maarit.Kokki@ecdc.europa.eu.
  • Kramarz P; European Center for Disease Prevention and Control, Gustav III:s boulevard 40, 169 73 Solna, Sweden. Electronic address: Piotr.Kramarz@ecdc.europa.eu.
  • Kurz X; European Medicines Agency, 30 Churchill Pl, Canary Wharf, London E14 5EU, UK. Electronic address: Xavier.Kurz@ema.europa.eu.
  • Larson HJ; London School of Hygiene & Tropical Medicine, Keppel St, Bloomsbury, London WC1E 7HT, UK. Electronic address: heidi.larson@lshtm.ac.uk.
  • de Lusignan S; University of Surrey, Guildford, Surrey GU2 7XH, UK; Royal College of General Practitioners, 30 Euston Square, London NW1 2FB, UK. Electronic address: s.lusignan@surrey.ac.uk.
  • Mahy P; Sciensano, Rue Juliette Wytsmanstraat 14, 1050 Brussels, Belgium. Electronic address: Patrick.Mahy@sciensano.be.
  • Torcel-Pagnon L; Vaccine Epidemiology and Modelling (VEM), Sanofi Pasteur, Campus SANOFI LYON, 14 Espace Henry Vallée, 69007 Lyon, France. Electronic address: Laurence.Pagnon@sanofi.com.
  • Titievsky L; Pfizer, 219 East 42nd St, NY, NY 10017, USA. Electronic address: lina.titievsky@pfizer.com.
  • Bauchau V; GSK-Vaccines, Av. Fleming 20, 1300 Wavre, Belgium. Electronic address: vincent.g.bauchau@gsk.com.
Vaccine ; 38 Suppl 2: B1-B7, 2020 12 22.
Article en En | MEDLINE | ID: mdl-31677952
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacunas / Gripe Humana / Subtipo H1N1 del Virus de la Influenza A Tipo de estudio: Screening_studies Límite: Humans País como asunto: Europa Idioma: En Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacunas / Gripe Humana / Subtipo H1N1 del Virus de la Influenza A Tipo de estudio: Screening_studies Límite: Humans País como asunto: Europa Idioma: En Año: 2020 Tipo del documento: Article